Open Orphan Plc's (LON:ORPH) Cathal Friel speaks to Proactive London's Andrew Scott after announcing plans to make its Venn Life Sciences business profitable by way of a three-year preferred partnership agreement with French pharma company Ipsen Group.
Friel says the deal is the first of many steps to make Venn profitable and deliver a re-rating of the business.